Active — Not RecruitingNot Applicable

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

China30 participantsStarted 2025-07-10

Plain-language summary

To Observe and Evaluate the Safety Profile of Trastuzumab Rezetecan Alone or in Combination in Patients with HER-2 Protein-Expressing Recurrent or Metastatic Malignant Solid Tumors in a Real-World Setting.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Sign the informed consent form voluntarily and agree to participate in this study.
✓. Histologically or cytologically confirmed diagnosis of advanced solid tumor.
✓. Age ≥ 18 years.
✓. HER2 protein expression (including IHC 1+, IHC 2+, IHC 3+, or IHC 0 with ≤10% of invasive tumor cells showing incomplete/weak membrane staining). HER2 protein expression test results must be within 2 years.
✓. Patients with advanced solid tumors who have failed, are intolerant to, or refuse standard therapy, and are deemed by the investigator as suitable to receive Trastuzumab Rezetecan monotherapy or combination therapy.

Exclusion criteria

✕. Patients who are concurrently receiving other therapies of the same class.
✕. Patients currently enrolled in another interventional clinical study.
✕. Females with confirmed pregnancy or during lactation.
✕. Any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in this study.

What they're measuring

Safety （Incidence of Grade ≥3 AEs）

Timeframe: From the first dose on Day 1 through the last dose, for up to 3 years

Trial details

NCT IDNCT07387874

SponsorLixiaoling

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-07

View on ClinicalTrials.gov More Recurrent or Metastatic Solid Tumors trials